Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) on Wednesday announced the launch of the CorEvitas Adolescent Alopecia Areata (AA) Registry to address the need for real-world, adolescent-specific data on this autoimmune condition.

The international registry will support research on disease burden, treatment effectiveness, and safety.

Now active in Europe and the United States., the registry recently enrolled its first patients in both regions. It is the 12th independent CorEvitas registry, complementing an existing adult AA registry launched in 2023. The initiative operates under the guidance of dermatology experts from Yale School of Medicine, Harvard Medical School, and Dermatology Physicians of Connecticut.

Designed to collect data on safety events, medication patterns, and treatment outcomes, the registry will track adolescent AA patients over time. AA affects approximately 2% of the global population, with many cases emerging in childhood or adolescence. The condition is associated with psychosocial challenges and a higher prevalence of other autoimmune diseases.

CorEvitas, part of Thermo Fisher Scientific's PPD clinical research business, provides regulatory-grade patient data across multiple disease areas. Its independent registry model has been recognized by regulators for long-term post-authorization safety studies.